Shire Plc has agreed to a US Food and Drug Administration request to study its stimulant Vyvanse in preschool children as concern rises over the diagnosis and treatment of attention deficit hyperactivity disorder the drugmaker said on Thursday A report last year by the Centers for Disease Control and Prevention found that the number of children diagnosed with ADHD increased  percent from  to  and that  million children or  percent of those aged  to  have been   Drug treatments include Ritalin Adderall and Vyvanse Only Adderall which is also made by Shire is approved to treat children under the age of  Yet   and the FDA wants additional information to ensure they are safe in this very young population Gwen Fisher a spokeswoman for UKbased Shire said the company is designing three clinical trials for children aged  to  One will examine how the body absorbs breaks down and excretes drugs Another will test for safety and efficacy A third will test for safety over a longer period  The company said it expects to launch the trials in the first half of  ADHD patients have difficulty paying attention and may have poor impulse control Most drugs that treat the condition are   which paradoxically can help organize thoughts and calm behavior But the drugs have been associated with growth suppression in children and they can also cause hallucinations mania and delusions Very little research has been done on the effect of stimulants in children A search by researchers from the Mario Negri Institute for Pharmacological Research in Milan Italy found just six studies that monitored a total of  children for side effects for at least  weeks Worldwide sales of Vyvanse grew  percent in the first quarter to  million